1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Eutrophication	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	natural	_	_	JJ	_	_	_	_	_
4	water	_	_	NN	_	_	_	_	_
5	sources	_	_	NNS	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	closely	_	_	RB	_	_	_	_	_
8	linked	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	distinctive	_	_	JJ	_	_	_	_	_
12	appearance	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	massive	_	_	JJ	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	episodic	_	_	JJ	_	_	_	_	_
17	proliferations	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	cyanobacteria	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	prokaryotic	_	_	JJ	_	_	_	_	_
3	organisms	_	_	NNS	_	_	_	_	_
4	do	_	_	VBP	_	_	_	_	_
5	not	_	_	RB	_	_	_	_	_
6	systematically	_	_	RB	_	_	_	_	_
7	carry	_	_	VB	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	expressed	_	_	VBN	_	_	_	_	_
10	genes	_	_	NNS	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	toxin	_	_	NN	_	_	_	_	_
13	production	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	yet	_	_	CC	_	_	_	_	_
16	about	_	_	RB	_	_	_	_	_
17	40	_	_	CD	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	150	_	_	CD	_	_	_	_	_
21	cyanobacteria	_	_	NN	_	_	_	_	_
22	genera	_	_	NNS	_	_	_	_	_
23	do	_	_	VBP	_	_	_	_	_
24	possess	_	_	VB	_	_	_	_	_
25	these	_	_	DT	_	_	_	_	_
26	genes	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	more	_	_	JJR	_	_	_	_	_
3	than	_	_	IN	_	_	_	_	_
4	two	_	_	CD	_	_	_	_	_
5	decades	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	microcystins	_	_	NNS	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	MCs	_	_	NNP	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	have	_	_	VBP	_	_	_	_	_
12	been	_	_	VBN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	main	_	_	JJ	_	_	_	_	_
15	family	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	cyanopeptides	_	_	NNS	_	_	_	_	_
18	extensively	_	_	RB	_	_	_	_	_
19	studied	_	_	VBN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	dominance	_	_	NN	_	_	_	_	_
3	has	_	_	VBZ	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	triggered	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	tragic	_	_	JJ	_	_	_	_	_
8	incidents	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	such	_	_	JJ	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	Brazilian	_	_	JJ	_	_	_	_	_
15	hospital	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	1996	_	_	CD	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	where	_	_	WRB	_	_	_	_	_
20	52	_	_	CD	_	_	_	_	_
21	patients	_	_	NNS	_	_	_	_	_
22	undergoing	_	_	VBG	_	_	_	_	_
23	dialysis	_	_	NN	_	_	_	_	_
24	succumbed	_	_	VBD	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	liver	_	_	NN	_	_	_	_	_
27	failure	_	_	NN	_	_	_	_	_
28	caused	_	_	VBN	_	_	_	_	_
29	by	_	_	IN	_	_	_	_	_
30	contaminated	_	_	VBN	_	_	_	_	_
31	water	_	_	NN	_	_	_	_	_
32	with	_	_	IN	_	_	_	_	_
33	MCs	_	_	NNP	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Following	_	_	VBG	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	World	_	_	NNP	_	_	_	_	_
6	Health	_	_	NNP	_	_	_	_	_
7	Organization	_	_	NNP	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	WHO	_	_	NNP	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	has	_	_	VBZ	_	_	_	_	_
12	suggested	_	_	VBN	_	_	_	_	_
13	regulation	_	_	NN	_	_	_	_	_
14	levels	_	_	NNS	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	MC-LR	_	_	NNP	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	drinking	_	_	NN	_	_	_	_	_
19	water	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	1	_	_	CD	_	_	_	_	_
22	µg	_	_	NN	_	_	_	_	_
23	L−1	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	which	_	_	WDT	_	_	_	_	_
26	was	_	_	VBD	_	_	_	_	_
27	extended	_	_	VBN	_	_	_	_	_
28	by	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	US	_	_	NNP	_	_	_	_	_
31	EPA	_	_	NNP	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	MC-LR	_	_	NNP	_	_	_	_	_
34	equivalents	_	_	NNS	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	include	_	_	VB	_	_	_	_	_
37	more	_	_	JJR	_	_	_	_	_
38	congeners	_	_	NNS	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	other	_	_	JJ	_	_	_	_	_
41	cyanotoxins	_	_	NNS	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	several	_	_	JJ	_	_	_	_	_
4	families	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	cyanopeptides	_	_	NNS	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	long	_	_	RB	_	_	_	_	_
9	been	_	_	VBN	_	_	_	_	_
10	identified	_	_	VBN	_	_	_	_	_
11	along	_	_	IN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	MCs	_	_	NNP	_	_	_	_	_
14	isolated	_	_	VBN	_	_	_	_	_
15	from	_	_	IN	_	_	_	_	_
16	common	_	_	JJ	_	_	_	_	_
17	cyanobacteria	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	i.	_	_	FW	_	_	_	_	_
20	e.	_	_	FW	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	Microcystis	_	_	NNP	_	_	_	_	_
23	sp	_	_	NNP	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Amongst	_	_	IN	_	_	_	_	_
2	them	_	_	PRP	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	cyanopeptolins	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	anabaenopeptins	_	_	NNS	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	APs	_	_	NNS	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	aerucyclamides	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	aeruginosines	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	microginins	_	_	NNS	_	_	_	_	_
17	are	_	_	VBP	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	mention	_	_	VB	_	_	_	_	_
20	when	_	_	WRB	_	_	_	_	_
21	specifying	_	_	VBG	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	dominant	_	_	JJ	_	_	_	_	_
24	families	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Still	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	high	_	_	JJ	_	_	_	_	_
5	diversity	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	produced	_	_	VBN	_	_	_	_	_
8	congeners	_	_	NNS	_	_	_	_	_
9	from	_	_	IN	_	_	_	_	_
10	each	_	_	DT	_	_	_	_	_
11	family	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	little	_	_	JJ	_	_	_	_	_
15	information	_	_	NN	_	_	_	_	_
16	known	_	_	VBN	_	_	_	_	_
17	about	_	_	IN	_	_	_	_	_
18	factors	_	_	NNS	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	mechanisms	_	_	NNS	_	_	_	_	_
21	linked	_	_	VBN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	their	_	_	PRP$	_	_	_	_	_
24	production	_	_	NN	_	_	_	_	_
25	greatly	_	_	RB	_	_	_	_	_
26	complicates	_	_	VBZ	_	_	_	_	_
27	their	_	_	PRP$	_	_	_	_	_
28	study	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Potential	_	_	JJ	_	_	_	_	_
2	cyanopeptides	_	_	NNS	_	_	_	_	_
3	toxicity	_	_	NN	_	_	_	_	_
4	critically	_	_	RB	_	_	_	_	_
5	depends	_	_	VBZ	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	variants	_	_	NNS	_	_	_	_	_
9	structure	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	but	_	_	CC	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	still	_	_	RB	_	_	_	_	_
14	misunderstood	_	_	VBN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	poorly	_	_	RB	_	_	_	_	_
17	documented	_	_	VBN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	MCs	_	_	NNS	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	hepatotoxic	_	_	JJ	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	readily	_	_	RB	_	_	_	_	_
6	accumulated	_	_	VBN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	liver	_	_	NN	_	_	_	_	_
10	from	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	specific	_	_	JJ	_	_	_	_	_
13	binding	_	_	NN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	protein	_	_	NN	_	_	_	_	_
16	phosphatases	_	_	NNS	_	_	_	_	_
17	1	_	_	CD	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	2A	_	_	CD	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	latter	_	_	NN	_	_	_	_	_
3	causes	_	_	VBZ	_	_	_	_	_
4	disruption	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	cellular	_	_	JJ	_	_	_	_	_
7	homeostasis	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	most	_	_	RBS	_	_	_	_	_
13	acute	_	_	JJ	_	_	_	_	_
14	cases	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	leads	_	_	VBZ	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	liver	_	_	NN	_	_	_	_	_
19	necrosis	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	as	_	_	RB	_	_	_	_	_
22	well	_	_	RB	_	_	_	_	_
23	as	_	_	IN	_	_	_	_	_
24	colorectal	_	_	JJ	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	liver	_	_	NN	_	_	_	_	_
27	cancer	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	far	_	_	RB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	bioactive	_	_	JJ	_	_	_	_	_
5	APs	_	_	NN	_	_	_	_	_
6	are	_	_	VBP	_	_	_	_	_
7	considered	_	_	VBN	_	_	_	_	_
8	non-toxic	_	_	JJ	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	Nevertheless	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	few	_	_	JJ	_	_	_	_	_
5	studies	_	_	NNS	_	_	_	_	_
6	suggest	_	_	VBP	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	some	_	_	DT	_	_	_	_	_
9	APs	_	_	NN	_	_	_	_	_
10	congeners	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	such	_	_	JJ	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	AP-A	_	_	NNP	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	may	_	_	MD	_	_	_	_	_
17	demonstrate	_	_	VB	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	potential	_	_	NN	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	inhibit	_	_	VB	_	_	_	_	_
22	protease	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	protein	_	_	NN	_	_	_	_	_
25	phosphatases	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	AP-B	_	_	NNP	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	-F	_	_	NN	_	_	_	_	_
6	induce	_	_	VB	_	_	_	_	_
7	cyanobacteria	_	_	NN	_	_	_	_	_
8	lysis	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	ultimately	_	_	RB	_	_	_	_	_
11	affecting	_	_	VBG	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	bioavailability	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	other	_	_	JJ	_	_	_	_	_
16	cell-bound	_	_	JJ	_	_	_	_	_
17	cyanotoxins	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Accordingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	much	_	_	RB	_	_	_	_	_
4	still	_	_	RB	_	_	_	_	_
5	needs	_	_	VBZ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	done	_	_	VBN	_	_	_	_	_
9	on	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	unambiguous	_	_	JJ	_	_	_	_	_
12	identification	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	these	_	_	DT	_	_	_	_	_
15	cyanopeptides	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	assessment	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	their	_	_	PRP$	_	_	_	_	_
21	potential	_	_	JJ	_	_	_	_	_
22	toxicity	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Cyanopeptide	_	_	NN	_	_	_	_	_
2	’s	_	_	POS	_	_	_	_	_
3	structures	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	characterized	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	cyclic	_	_	JJ	_	_	_	_	_
8	or	_	_	CC	_	_	_	_	_
9	linear	_	_	JJ	_	_	_	_	_
10	non-ribosomal	_	_	JJ	_	_	_	_	_
11	peptides	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	each	_	_	DT	_	_	_	_	_
14	family	_	_	NN	_	_	_	_	_
15	possessing	_	_	VBG	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	characteristic	_	_	JJ	_	_	_	_	_
18	substructure	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	some	_	_	DT	_	_	_	_	_
21	variable	_	_	JJ	_	_	_	_	_
22	amino	_	_	JJ	_	_	_	_	_
23	acids	_	_	NNS	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	peptides	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	variations	_	_	NNS	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	core	_	_	JJ	_	_	_	_	_
6	structure	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	each	_	_	DT	_	_	_	_	_
9	cyanopeptide	_	_	NN	_	_	_	_	_
10	multiply	_	_	VBP	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	number	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	combinations	_	_	NNS	_	_	_	_	_
15	which	_	_	WDT	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	cause	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	large	_	_	JJ	_	_	_	_	_
22	variety	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	potential	_	_	JJ	_	_	_	_	_
25	congeners	_	_	NNS	_	_	_	_	_
26	;	_	_	:	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	date	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	more	_	_	JJR	_	_	_	_	_
31	than	_	_	IN	_	_	_	_	_
32	500	_	_	CD	_	_	_	_	_
33	cyanopeptides	_	_	NNS	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	including	_	_	VBG	_	_	_	_	_
36	240	_	_	CD	_	_	_	_	_
37	MCs	_	_	NNS	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	96	_	_	CD	_	_	_	_	_
40	APs	_	_	NNS	_	_	_	_	_
41	have	_	_	VBP	_	_	_	_	_
42	been	_	_	VBN	_	_	_	_	_
43	identified	_	_	VBN	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	More	_	_	RBR	_	_	_	_	_
2	specifically	_	_	RB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	MCs	_	_	NNP	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	cyclic	_	_	JJ	_	_	_	_	_
7	heptapeptides	_	_	NNS	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	1	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	characteristic	_	_	JJ	_	_	_	_	_
5	β-amino	_	_	NN	_	_	_	_	_
6	acid	_	_	NN	_	_	_	_	_
7	moiety	_	_	NN	_	_	_	_	_
8	named	_	_	VBN	_	_	_	_	_
9	Adda	_	_	NNP	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic	_	_	NNP	_	_	_	_	_
12	acid	_	_	NN	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	two	_	_	CD	_	_	_	_	_
17	distinctive	_	_	JJ	_	_	_	_	_
18	positions	_	_	NNS	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	highest	_	_	JJS	_	_	_	_	_
22	variation	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	monomers	_	_	NNS	_	_	_	_	_
25	(	_	_	-LRB-	_	_	_	_	_
26	X	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	Z	_	_	NN	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	APs	_	_	NN	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	cyclic	_	_	JJ	_	_	_	_	_
4	peptides	_	_	NNS	_	_	_	_	_
5	bound	_	_	VBN	_	_	_	_	_
6	through	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	characteristic	_	_	JJ	_	_	_	_	_
9	ureido-linkage	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	1	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	;	_	_	:	_	_	_	_	_
3	their	_	_	PRP$	_	_	_	_	_
4	structure	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	characterized	_	_	VBN	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	following	_	_	VBG	_	_	_	_	_
10	:	_	_	:	_	_	_	_	_
11	AA1-CO-[Lys-AA3-AA4-MeAA5-AA6	_	_	NNP	_	_	_	_	_
12	]	_	_	-RRB-	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	AA	_	_	NNP	_	_	_	_	_
15	representing	_	_	VBG	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	variable	_	_	JJ	_	_	_	_	_
18	amino	_	_	JJ	_	_	_	_	_
19	acid	_	_	NN	_	_	_	_	_
20	residues	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	brackets	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	including	_	_	VBG	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	cyclic	_	_	JJ	_	_	_	_	_
27	structure	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Based	_	_	VBN	_	_	_	_	_
2	on	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	various	_	_	JJ	_	_	_	_	_
5	amino	_	_	JJ	_	_	_	_	_
6	acid	_	_	NN	_	_	_	_	_
7	combinations	_	_	NNS	_	_	_	_	_
8	identified	_	_	VBN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	these	_	_	DT	_	_	_	_	_
11	two	_	_	CD	_	_	_	_	_
12	families	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	an	_	_	DT	_	_	_	_	_
15	extensive	_	_	JJ	_	_	_	_	_
16	list	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	potential	_	_	JJ	_	_	_	_	_
19	amino	_	_	JJ	_	_	_	_	_
20	acids	_	_	NNS	_	_	_	_	_
21	per	_	_	IN	_	_	_	_	_
22	variable	_	_	JJ	_	_	_	_	_
23	sites	_	_	NNS	_	_	_	_	_
24	can	_	_	MD	_	_	_	_	_
25	be	_	_	VB	_	_	_	_	_
26	proposed	_	_	VBN	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	enumerate	_	_	VB	_	_	_	_	_
29	all	_	_	DT	_	_	_	_	_
30	possible	_	_	JJ	_	_	_	_	_
31	theoretical	_	_	JJ	_	_	_	_	_
32	combinations	_	_	NNS	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	cyanopeptides	_	_	NNS	_	_	_	_	_
35	identifiable	_	_	JJ	_	_	_	_	_
36	to	_	_	TO	_	_	_	_	_
37	date	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Based	_	_	VBN	_	_	_	_	_
2	on	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	proposed	_	_	VBN	_	_	_	_	_
5	combinations	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	one	_	_	CD	_	_	_	_	_
8	could	_	_	MD	_	_	_	_	_
9	theoretically	_	_	RB	_	_	_	_	_
10	propose	_	_	VB	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	significantly	_	_	RB	_	_	_	_	_
13	higher	_	_	JJR	_	_	_	_	_
14	number	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	congeners	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	although	_	_	IN	_	_	_	_	_
19	most	_	_	JJS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	variants	_	_	NNS	_	_	_	_	_
23	may	_	_	MD	_	_	_	_	_
24	not	_	_	RB	_	_	_	_	_
25	occur	_	_	VB	_	_	_	_	_
26	naturally	_	_	RB	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	practice	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	due	_	_	JJ	_	_	_	_	_
31	to	_	_	TO	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	low	_	_	JJ	_	_	_	_	_
34	frequency	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	some	_	_	DT	_	_	_	_	_
37	amino	_	_	JJ	_	_	_	_	_
38	acids	_	_	NNS	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	the	_	_	DT	_	_	_	_	_
41	possible	_	_	JJ	_	_	_	_	_
42	combinations	_	_	NNS	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	High-resolution	_	_	JJ	_	_	_	_	_
2	mass	_	_	NN	_	_	_	_	_
3	spectrometry	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	HRMS	_	_	NN	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	can	_	_	MD	_	_	_	_	_
8	use	_	_	VB	_	_	_	_	_
9	exact	_	_	JJ	_	_	_	_	_
10	mass	_	_	NN	_	_	_	_	_
11	measurement	_	_	NN	_	_	_	_	_
12	coupled	_	_	VBN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	database	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	software	_	_	NN	_	_	_	_	_
17	packages	_	_	NNS	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	become	_	_	VB	_	_	_	_	_
20	an	_	_	DT	_	_	_	_	_
21	increasingly	_	_	RB	_	_	_	_	_
22	more	_	_	RBR	_	_	_	_	_
23	effective	_	_	JJ	_	_	_	_	_
24	tool	_	_	NN	_	_	_	_	_
25	regarding	_	_	VBG	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	accurate	_	_	JJ	_	_	_	_	_
28	identification	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	suspect	_	_	JJ	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	unknown	_	_	JJ	_	_	_	_	_
34	compounds	_	_	NNS	_	_	_	_	_
35	without	_	_	IN	_	_	_	_	_
36	the	_	_	DT	_	_	_	_	_
37	use	_	_	NN	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	certified	_	_	VBN	_	_	_	_	_
40	standards	_	_	NNS	_	_	_	_	_
41	,	_	_	,	_	_	_	_	_
42	where	_	_	WRB	_	_	_	_	_
43	target	_	_	NN	_	_	_	_	_
44	analysis	_	_	NN	_	_	_	_	_
45	is	_	_	VBZ	_	_	_	_	_
46	unfeasible	_	_	JJ	_	_	_	_	_
47	.	_	_	.	_	_	_	_	_


1	Suspect	_	_	NN	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	non-target	_	_	JJ	_	_	_	_	_
4	screening	_	_	NN	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	two	_	_	CD	_	_	_	_	_
8	main	_	_	JJ	_	_	_	_	_
9	strategies	_	_	NNS	_	_	_	_	_
10	used	_	_	VBN	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	exhaustive	_	_	JJ	_	_	_	_	_
14	search	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	known	_	_	VBN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	unknown	_	_	JJ	_	_	_	_	_
20	compound	_	_	NN	_	_	_	_	_
21	where	_	_	WRB	_	_	_	_	_
22	almost	_	_	RB	_	_	_	_	_
23	no	_	_	DT	_	_	_	_	_
24	reference	_	_	NN	_	_	_	_	_
25	material	_	_	NN	_	_	_	_	_
26	is	_	_	VBZ	_	_	_	_	_
27	available	_	_	JJ	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	recent	_	_	JJ	_	_	_	_	_
3	years	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	use	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	these	_	_	DT	_	_	_	_	_
9	screening	_	_	NN	_	_	_	_	_
10	techniques	_	_	NNS	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	environmental	_	_	JJ	_	_	_	_	_
14	field	_	_	NN	_	_	_	_	_
15	has	_	_	VBZ	_	_	_	_	_
16	greatly	_	_	RB	_	_	_	_	_
17	increased	_	_	VBN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	particularly	_	_	RB	_	_	_	_	_
20	for	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	non-target	_	_	JJ	_	_	_	_	_
23	analysis	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	pharmaceuticals	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	pesticides	_	_	NNS	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	hormones	_	_	NNS	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	surface	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	treated	_	_	VBN	_	_	_	_	_
34	water	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Reversewise	_	_	JJ	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	presence	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	cyanotoxins	_	_	NNS	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	surface	_	_	NN	_	_	_	_	_
9	water	_	_	NN	_	_	_	_	_
10	has	_	_	VBZ	_	_	_	_	_
11	only	_	_	RB	_	_	_	_	_
12	been	_	_	VBN	_	_	_	_	_
13	investigated	_	_	VBN	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	few	_	_	JJ	_	_	_	_	_
16	authors	_	_	NNS	_	_	_	_	_
17	using	_	_	VBG	_	_	_	_	_
18	this	_	_	DT	_	_	_	_	_
19	type	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	analysis	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Isobaric	_	_	JJ	_	_	_	_	_
2	interferences	_	_	NNS	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	co-eluting	_	_	NN	_	_	_	_	_
5	substances	_	_	NNS	_	_	_	_	_
6	can	_	_	MD	_	_	_	_	_
7	represent	_	_	VB	_	_	_	_	_
8	major	_	_	JJ	_	_	_	_	_
9	challenges	_	_	NNS	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	identification	_	_	NN	_	_	_	_	_
13	process	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	compound	_	_	NN	_	_	_	_	_
17	even	_	_	RB	_	_	_	_	_
18	when	_	_	WRB	_	_	_	_	_
19	using	_	_	VBG	_	_	_	_	_
20	HRMS	_	_	NNP	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	sole	_	_	JJ	_	_	_	_	_
5	analysis	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	based	_	_	VBN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	accurate	_	_	JJ	_	_	_	_	_
11	mass	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	insufficient	_	_	JJ	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	confirm	_	_	VB	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	structural	_	_	JJ	_	_	_	_	_
19	identification	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	e.	_	_	FW	_	_	_	_	_
22	g.	_	_	FW	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	determining	_	_	VBG	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	degradation	_	_	NN	_	_	_	_	_
27	by-products	_	_	NNS	_	_	_	_	_
28	or	_	_	CC	_	_	_	_	_
29	metabolites	_	_	NNS	_	_	_	_	_
30	related	_	_	VBN	_	_	_	_	_
31	to	_	_	TO	_	_	_	_	_
32	a	_	_	DT	_	_	_	_	_
33	compound	_	_	NN	_	_	_	_	_
34	of	_	_	IN	_	_	_	_	_
35	interest	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	non-target	_	_	JJ	_	_	_	_	_
3	screening	_	_	NN	_	_	_	_	_
4	method	_	_	NN	_	_	_	_	_
5	should	_	_	MD	_	_	_	_	_
6	include	_	_	VB	_	_	_	_	_
7	various	_	_	JJ	_	_	_	_	_
8	confirmatory	_	_	JJ	_	_	_	_	_
9	elements	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	such	_	_	JJ	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	accurate	_	_	JJ	_	_	_	_	_
15	mass	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	m/z	_	_	NN	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	mass	_	_	NN	_	_	_	_	_
21	defect	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	isotopic	_	_	JJ	_	_	_	_	_
24	pattern	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	charge	_	_	NN	_	_	_	_	_
27	states	_	_	NNS	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	adducts	_	_	NNS	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	fragmentation	_	_	NN	_	_	_	_	_
32	pattern	_	_	NN	_	_	_	_	_
33	that	_	_	WDT	_	_	_	_	_
34	increase	_	_	VBP	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	confidence	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	identification	_	_	NN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Suspect	_	_	NN	_	_	_	_	_
2	screening	_	_	NN	_	_	_	_	_
3	includes	_	_	VBZ	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	benefit	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	disadvantage	_	_	NN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	depend	_	_	VB	_	_	_	_	_
10	on	_	_	IN	_	_	_	_	_
11	suspect	_	_	NN	_	_	_	_	_
12	lists	_	_	NNS	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	mainly	_	_	RB	_	_	_	_	_
4	based	_	_	VBN	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	some	_	_	DT	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	information	_	_	NN	_	_	_	_	_
10	mentioned	_	_	VBN	_	_	_	_	_
11	above	_	_	RB	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	identification	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	but	_	_	CC	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	major	_	_	JJ	_	_	_	_	_
19	drawback	_	_	NN	_	_	_	_	_
20	comes	_	_	VBZ	_	_	_	_	_
21	from	_	_	IN	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	lack	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	data	_	_	NNS	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	online	_	_	JJ	_	_	_	_	_
28	libraries	_	_	NNS	_	_	_	_	_
29	for	_	_	IN	_	_	_	_	_
30	some	_	_	DT	_	_	_	_	_
31	small	_	_	JJ	_	_	_	_	_
32	molecule	_	_	NN	_	_	_	_	_
33	families	_	_	NNS	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	i.	_	_	FW	_	_	_	_	_
36	e.	_	_	FW	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	cyanotoxins	_	_	NNS	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	which	_	_	WDT	_	_	_	_	_
41	allow	_	_	VBP	_	_	_	_	_
42	a	_	_	DT	_	_	_	_	_
43	formal	_	_	JJ	_	_	_	_	_
44	identification	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	Nonetheless	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	considering	_	_	VBG	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	possibility	_	_	NN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	build	_	_	VB	_	_	_	_	_
8	specific	_	_	JJ	_	_	_	_	_
9	in-house	_	_	JJ	_	_	_	_	_
10	databases	_	_	NNS	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	unambiguous	_	_	JJ	_	_	_	_	_
14	identification	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	known	_	_	VBN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	unknown	_	_	JJ	_	_	_	_	_
20	cyanopeptides	_	_	NNS	_	_	_	_	_
21	is	_	_	VBZ	_	_	_	_	_
22	promising	_	_	JJ	_	_	_	_	_
23	for	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	study	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	identification	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	less	_	_	RBR	_	_	_	_	_
30	known	_	_	VBN	_	_	_	_	_
31	congeners	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_

